TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9380285

Group type: EXPERIMENTAL
Intervention: Clonidine (105 micrograms) in addition to bupivacaine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 1%
Number of subjects: 56
Study: 7995682

Group type: EXPERIMENTAL
Intervention: Galactosamino-glycuronoglycan-sulfate (GGGS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3737040

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment before repeat cytology
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Reexamination before three months
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Patients who failed to revert to normal cytology on repeat examination
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Patients with initial cytology demonstrating marked atypia unassociated with inflammation
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Follow up and histologic diagnosis for 110 patients
Number of subjects: 512
Study: 28852839

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1012
Study: 26981758

Group type: EXPERIMENTAL
Intervention: End-rounded bristles with dentifrice
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tapered bristles with dentifrice
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: End-rounded bristles without dentifrice
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tapered bristles without dentifrice
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dentifrice (used with both bristle types)
Number of subjects: 39
Study: 24830716

Group type: EXPERIMENTAL
Intervention: Peer assessment group (n=49)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Case-based discussion group (control group) (n=41)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 22323685

Group type: EXPERIMENTAL
Intervention: Computerised navigation TKR (group B, 98 knees)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Conventional TKR (group A, 97 knees)
Number of subjects: 195
Study: 20675027

Group type: EXPERIMENTAL
Intervention: Size constant stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Size variable stimuli
Number of subjects: 0
Study: 17900705

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (EPA+DHA) 3 g daily for 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 24
Study: 15641931

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 144
Study: 11895159

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (enteral and parenteral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12607270

Group type: EXPERIMENTAL
Intervention: Ketamine (group K, n = 18)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Pentazocine (group P, n = 19)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Flurbiprofen axetil (group F, n = 18)
Number of subjects: 55
Study: 9419170

Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 310

Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 310
Study: 8582096

Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) 400 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 2671220

Group type: EXPERIMENTAL
Intervention: Oxymetazoline (doses and concentrations traditionally used)
Number of subjects: 106
Study: 939445

Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-Tourniquet (elevated hand table)
Number of subjects: 2
Study: 30260794

Group type: COMPARATOR
Intervention: Pressure pain thresholds
Number of subjects: 42

Group type: COMPARATOR
Intervention: Heat pain thresholds
Number of subjects: 42

Group type: COMPARATOR
Intervention: Variability for pressure pain thresholds
Number of subjects: 42

Group type: COMPARATOR
Intervention: Variability for heat pain thresholds
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mid-line lower range
Number of subjects: 42
Study: 28431060

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Chronic antiarrhythmic drug (AAD) therapy with bisoprolol (5 mg od) and/or diltiazem (120-300 mg od)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Chronic antiarrhythmic drug (AAD) therapy
Number of subjects: 61
Study: 25288674

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI) 40 IU
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intranasal placebo (INP)
Number of subjects: 8
Study: 23117071

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.5 mg/m² (24‐h infusion every 3 weeks)
Number of subjects: 279
Study: 21762992

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 872

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 872
Study: 19132345

Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-navigated TKA
Number of subjects: 100
Study: 17100937

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Sildenafil 100 mg (2 x 50 mg encapsulated tablets)
Number of subjects: 1057
Study: 15149510

Group type: EXPERIMENTAL
Intervention: Inositol supplements
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 15
Study: 11522873

Group type: EXPERIMENTAL
Intervention: Intermittent intravenous iron infusions (200 mg every 2 months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Daily oral iron supplements (210 mg elemental iron per day)
Number of subjects: 28
Study: 9050955

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (8 mg/m2 I.V. infusion every month for 1 year)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (I.V. infusion of saline every month for 1 year)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 51
Study: 8090084

Group type: EXPERIMENTAL
Intervention: Patients with multiple sclerosis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study: 3013033

Group type: EXPERIMENTAL
Intervention: Prostaglandin precursor essential fatty acids
Number of subjects: 16
Study: 30640245

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (3 mg/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Peritonsillar infiltration with bupivacaine (5 ml, 0.25%)
Number of subjects: 200
Study: 28441325

Group type: EXPERIMENTAL
Intervention: Taekwondo training (TKD) for 60 min, 5 times per week, for 16 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no TKD training)
Number of subjects: 30
Study: 26643993

Group type: EXPERIMENTAL
Intervention: GSK1278863 50 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GSK1278863 100 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GSK1278863 (10 to 100 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GSK1278863
Number of subjects: 33
Study: 23821414

Group type: EXPERIMENTAL
Intervention: Riluzole (50 or 100 mg/day based on bodyweight) + Risperidone (up to 2 or 3 mg/day based on bodyweight)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo + Risperidone (up to 2 or 3 mg/day based on bodyweight)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Riluzole + Risperidone
Number of subjects: 49
Study: 21512509

Group type: EXPERIMENTAL
Intervention: 0.8% high-guluronate alginate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.6% high-guluronate alginate
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0% alginate (control)
Number of subjects: 23
Study: 18791776

Group type: EXPERIMENTAL
Intervention: Retinex filter
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Retinex filter combined with standard DICOM image
Number of subjects: 29

Group type: COMPARATOR
Intervention: Other filters and original DICOM image
Number of subjects: 29
Study: 17298708

Group type: EXPERIMENTAL
Intervention: 200 microg phylloquinone/d
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 500 microg phylloquinone/d
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 15098518

Group type: EXPERIMENTAL
Intervention: 26-gauge, 1/2-in needle
Number of subjects: 98

Group type: COMPARATOR
Intervention: 22-gauge, 1 1/2-in needle
Number of subjects: 98
Study: 11522145

Group type: EXPERIMENTAL
Intervention: Active warm-up
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Passive warm-up
Number of subjects: 8

Group type: COMPARATOR
Intervention: No warm-up (control)
Number of subjects: 8
Study: 9931699

Group type: EXPERIMENTAL
Intervention: Acute pain service
Number of subjects: 498

Group type: COMPARATOR
Intervention: Control group (without acute pain service)
Number of subjects: 498
Study: 7923646

Group type: EXPERIMENTAL
Intervention: Hirudin (0.4 mg/kg body wt bolus and 0.15 mg.kg‐1.h‐1) infused over 48 to 72 hours
Number of subjects: 302

Group type: COMPARATOR
Intervention: Heparin (70 IU/kg body wt bolus and 15 IU.kg‐1.h‐1) infused over 48 to 72 hours
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 302

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 302
Study: 3347519

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 51

Group type: COMPARATOR
Intervention: Left lateral position
Number of subjects: 51

Group type: COMPARATOR
Intervention: Right lateral position
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Vasoactive drugs or mechanical ventilation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cardiac index less than 2.3 L/min/m2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Time elapsed since surgery less than 12 hours
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Stroke volume
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 51
Study: 31634189

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 4114

Group type: COMPARATOR
Intervention: Antiretroviral therapy
Number of subjects: 4114

Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 4114
Study: 29189022

Group type: EXPERIMENTAL
Intervention: Counterattitudinal advocacy (CAA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 28499707

Group type: EXPERIMENTAL
Intervention: L‐SMILE (low energy: 100, 105, and 110 nJ)
Number of subjects: 151

Group type: COMPARATOR
Intervention: C‐SMILE (conventional energy: 115‐150 nJ)
Number of subjects: 151
Study: 26166077

Group type: EXPERIMENTAL
Intervention: H‐MRS (1H Magnetic Resonance Spectroscopy)
Number of subjects: 60
Study: 23859058

Group type: EXPERIMENTAL
Intervention: SoundBite
Number of subjects: 9

Group type: COMPARATOR
Intervention: BAHI
Number of subjects: 9
Study: 20881376

Group type: EXPERIMENTAL
Intervention: Erythromycin (125 mg, three times/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18245068

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous patient-controlled analgesia (PCA)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Preoperative IES scores
Number of subjects: 117
Study: 17001944

Group type: EXPERIMENTAL
Intervention: Urgotul wound dressing with TNP therapy
Number of subjects: 66
Study: 14570784

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 50
Study: 10868710

Group type: EXPERIMENTAL
Intervention: Bronchodilatation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cold air challenge (CACh)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Initial FEV1 (% predicted)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Asthma severity and sensitization to furred animals
Number of subjects: 55
Study: 8615359

Group type: EXPERIMENTAL
Intervention: Predigested formula A (12% linoleic acid)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Predigested formula B (7% linoleic acid)
Number of subjects: 76
Study: 1598464

Group type: EXPERIMENTAL
Intervention: 50 mg acetylsalicylic acid
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 50 mg acetylsalicylic acid plus 75 mg dipyridamole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2856892

Group type: EXPERIMENTAL
Intervention: Nadolol 10 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nadolol 20 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nadolol 40 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nadolol (all dosages)
Number of subjects: 46
Study: 30160168

Group type: EXPERIMENTAL
Intervention: BMAC injection
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 25
Study: 28719274

Group type: EXPERIMENTAL
Intervention: Never wore shoes at work
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Never wore shoes at home
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Washed feet at day end (versus immediately after work)
Number of subjects: 120
Study: 28186949

Group type: EXPERIMENTAL
Intervention: Scheduled appointments
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Standard open reminders
Number of subjects: 1087
Study: 24127249

Group type: EXPERIMENTAL
Intervention: Book provided during week 1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Book provided during week 4
Number of subjects: 20
Study: 22350194

Group type: EXPERIMENTAL
Intervention: Long-term Internet-delivered worksite health promotion programme with additional website functionalities (action-oriented feedback, self-monitoring, possibility to ask questions, monthly e-mail messages)
Number of subjects: 924

Group type: COMPARATOR
Intervention: Standard programme consisting of a physical health check with face-to-face advice and personal feedback on a website
Number of subjects: 924
Study: 19126830

Group type: EXPERIMENTAL
Intervention: Instalment prescription (n = 101)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Normal prescription (n = 103)
Number of subjects: 204
Study: 17906248

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 14747671

Group type: EXPERIMENTAL
Intervention: 10 mg daily iron supplementation
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg) every 3 months
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Both iron and mebendazole
Number of subjects: 459
Study: 11505342

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 8993242

Group type: EXPERIMENTAL
Intervention: Aprotinin (group A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal saline solution (group B)
Number of subjects: 19
Study: 8233775

Group type: EXPERIMENTAL
Intervention: CAT‐CAM socket
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: QUAD socket
Number of subjects: 30

Group type: COMPARATOR
Intervention: Faster pace
Number of subjects: 30
Study: 3113340

Group type: EXPERIMENTAL
Intervention: Futraful
Number of subjects: 232

Group type: COMPARATOR
Intervention: UFT
Number of subjects: 232
Study: 31588801

Group type: EXPERIMENTAL
Intervention: Direct anterior approach total hip arthroplasty (DA THA)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Posterior approach total hip arthroplasty
Number of subjects: 111
Study: 29396897

Group type: EXPERIMENTAL
Intervention: Internet-based brief intervention (IBI)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control (assessment only)
Number of subjects: 626
Study: 27181129

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on TCM diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 25070111

Group type: EXPERIMENTAL
Intervention: Chloroquine treatment
Number of subjects: 126
Study: 23354913

Group type: EXPERIMENTAL
Intervention: Stepped care treatment
Number of subjects: 293

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy
Number of subjects: 293
Study: 20826525

Group type: EXPERIMENTAL
Intervention: Exposure to 19°C
Number of subjects: 25
Study: 18461650

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 1404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1404
Study: 15879586

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs (olanzapine, perospirone, quetiapine, or risperidone)
Number of subjects: 86
Study: 12939003

Group type: EXPERIMENTAL
Intervention: Mandibular implant-retained overdenture (IOD)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Mandibular conventional denture (CD)
Number of subjects: 63
Study: 10930055

Group type: EXPERIMENTAL
Intervention: Sodium polystyrene sulfonate 30 g
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 6
Study: 8689424

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) daily bolus therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) continuous infusion (C.I.) therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) bolus therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control specimens
Number of subjects: 12
Study: 1735142

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 53
Study: 6389126

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 441

Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 441
Study: 31553410

Group type: EXPERIMENTAL
Intervention: Inclisiran (1 dose: 200, 300, or 500 mg on day 1)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Inclisiran (2 doses: 100, 200, or 300 mg on days 1 and 90)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Inclisiran (2 doses: 300 mg)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Inclisiran (1 or 2 doses)
Number of subjects: 501
Study: 29235159

Group type: EXPERIMENTAL
Intervention: Green tea ointment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 99
Study: 25995049

Group type: EXPERIMENTAL
Intervention: Small bowl
Number of subjects: 61

Group type: COMPARATOR
Intervention: Large bowl
Number of subjects: 61
Study: 24418526

Group type: EXPERIMENTAL
Intervention: CT-screening group
Number of subjects: 4104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4104

Group type: EXPERIMENTAL
Intervention: CT-screening group (excluding CT costs)
Number of subjects: 4104

Group type: EXPERIMENTAL
Intervention: True-positive group
Number of subjects: 4104

Group type: EXPERIMENTAL
Intervention: False-positive group
Number of subjects: 4104
Study: 22506760

Group type: EXPERIMENTAL
Intervention: Higher energy treatment with cryogen spray cooling (CSC) (10‐mm spot size; 50 J/cm(2); 50‐ms pulse duration and CSC settings of 30‐ms duration with a 20‐ms delay)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lower energy treatment with no CSC (10 mm; 20 J/cm(2); 50 ms)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 20159125

Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD) after a 7-week pulmonary rehabilitation program
Number of subjects: 75
Study: 17506788

Group type: EXPERIMENTAL
Intervention: Concurrent oxytocin infusion with dinoprostone pessary
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dinoprostone pessary alone (placebo)
Number of subjects: 0
Study: 16159821

Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits
Number of subjects: 12

Group type: COMPARATOR
Intervention: Protein-coated CPB circuits
Number of subjects: 12
Study: 12082182

Group type: EXPERIMENTAL
Intervention: Treatment using computer support to train patients to eat and recognize satiety, with physical activity restriction and resting in a warm room after eating.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group received no treatment.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Treatment to remission.
Number of subjects: 32
Study: 10460774

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (IOAB with, 29 eyes)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No dexamethasone (IOAB without, 34 eyes)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (IOAB with)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Intravitreal dexamethasone (IOAB with) and No dexamethasone (IOAB without)
Number of subjects: 63
Study: 8524724

Group type: EXPERIMENTAL
Intervention: Yearly preventive visits for 2 years and optional counseling visits to primary care provider
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 2259930

Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study: 6626409

Group type: EXPERIMENTAL
Intervention: Premedication with diazepam 5 mg rectally and atropine 0.3‐0.4 mg sublingually (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rectal solution including diazepam 0.5 mg kg‐1, morphine 0.15 mg kg‐1 and hyoscine 0.01 mg kg‐1 (Group B)
Number of subjects: 80
Study: 31561882

Group type: EXPERIMENTAL
Intervention: Empagliflozin added to standard of care (SoC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 0
Study: 29779922

Group type: EXPERIMENTAL
Intervention: NP-HA/FA (Nanopatch with split inactivated influenza virus applied to the volar forearm), n=15
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NP-HA/UA (Nanopatch with split inactivated influenza virus applied to the upper arm), n=15
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IM-HA/D (Intramuscular injection of Fluvax® 2016), n=15
Number of subjects: 60

Group type: COMPARATOR
Intervention: NP-placebo/FA (Nanopatch with excipients only applied to the volar forearm), n=5
Number of subjects: 60

Group type: COMPARATOR
Intervention: NP-placebo/UA (Nanopatch with excipients only applied to the upper arm), n=5
Number of subjects: 60

Group type: COMPARATOR
Intervention: IM-placebo/D (Saline injected IM into the deltoid), n=5
Number of subjects: 60